Evidence map›Paper›PMID 32387525›Full record

ArticleChest2020

Rurality, Stage-Stratified Use of Treatment Modalities, and Survival of Non-small Cell Lung Cancer.

Meredith A Ray, Nicholas R Faris, Anna Derrick, Matthew P Smeltzer, Raymond U Osarogiagbon

Open access · greenAbstract readMulticenter Study
In one paragraph

Article in Chest, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Impact of Medicaid expansion on stage of diagnosis of lung cancer for rural and urban patients in New Hampshire.The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association · 2025
    Article
  6. Review
  7. Area-based disparities in non-small-cell lung cancer survival.Acta oncologica (Stockholm, Sweden) · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Volume-Based Care Regionalization: Pitfalls and Challenges.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Meredith A RayDivision of Epidemiology, Biostatistics, and Environmental Health, School of Public Health, University of Memphis, Memphis, TN.
Nicholas R FarisMultidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis, TN.
Anna DerrickBaptist Memorial Health Care Corporation, Memphis, TN.
Matthew P SmeltzerDivision of Epidemiology, Biostatistics, and Environmental Health, School of Public Health, University of Memphis, Memphis, TN.
Raymond U OsarogiagbonMultidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis, TN. Electronic address: rosarogi@bmhcc.org.
University of Memphis · USBaptist Memorial Health Care · US

Funding

Improving pathologic nodal staging of resected lung cancerR01CA172253 · NCI · UNIVERSITY OF MEMPHIS · PI OSAROGIAGBON, RAYMOND U · 2013 to 2022
$4.8M
NCI NIH HHS R01 CA172253
6 · The paper itself

Abstract

backgroundTo eliminate them, non-small cell lung cancer (NSCLC) care and outcome disparities need to be better understood. RESEARCH QUESTION: How does rurality interact with NSCLC care and outcome disparities? STUDY DESIGN AND

methodsWe examined guideline-concordant use of active treatment for NSCLC across five institutions in one community-based health care system spanning 44% of the Delta Regional Authority catchment area from 2011 to 2017. Institution- and patient-level rurality were based on Rural-Urban Commuting Area codes. Chi-squared, F-tests, and logistic regressions were used to analyze differences across institutions and rurality; survival was examined using log-rank tests and Cox regression.

resultsOf 6,259 patients, 47% resided in rural areas; two of five institutions were rurally located and provided care for 20% of patients. Compared with rural residents at rural institutions, urban and rural residents attending urban institutions were more likely to receive stage-preferred treatment: OR 1.68 (95%CI, 1.44-1.96), and 1.33 (1.11-1.61), respectively, after adjusting for insurance, age, and clinical stage. Urban and rural residents attending urban institutions had a lower hazard of death compared with rural residents attending rural institutions: hazard ratio (HR) 0.69 (0.64-0.75) and 0.61 (0.55-0.67), respectively. Among recipients of stage-preferred treatment, care at urban institutions remained less hazardous: HR 0.7 (0.63-0.79). When further stratified by stage, care for late-stage patients at urban institutions remained less hazardous: HR 0.8 (0.71-0.91).

interpretationRurality-associated treatment and survival disparities were present at the patient and institution levels, but the institution-level disparity was greater. Rural residents receiving care at urban institutions had similar outcomes to urban residents receiving care at urban hospitals. To overcome rurality-associated NSCLC survival disparity, interventions should preferentially target the institution level, including expanding access to higher-quality guideline-concordant care.

Indexed as

Healthcare DisparitiesAgedCarcinoma, Non-Small-Cell LungFemaleHumansLung NeoplasmsMaleMiddle AgedNeoplasm StagingRural PopulationSurvival RateUnited Stateslung cancer care and outcome disparitiesnon-small cell lung cancerruralitysurvival

Identifiers

PMID32387525
PMCPMC7417381
OpenAlexW3022652006

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.